Literature DB >> 19956396

Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes.

Tanja Pejovic1, Nupur T Pande, Motomi Mori, Paulette Mhawech-Fauceglia, Christina Harrington, Solange Mongoue-Tchokote, Daniel Dim, Christopher Andrews, Amy Beck, Yukie Tarumi, Jovana Djilas, Fabio Cappuccini, Otavia Caballero, Jiaqi Huang, Samuel Levy, Alexia Tsiamouri, Joanna Cain, Grover C Bagby, Robert L Strausberg, Andrew J Simpson, Kunle O Odunsi.   

Abstract

OBJECTIVES: We tested the hypothesis that co-coordinated up-regulation or down-regulation of several ovarian cell surface kinases may provide clues for better understanding of the disease and help in rational design of therapeutic targets. STUDY
DESIGN: We compared the expression signature of 69 surface kinases in normal ovarian surface epithelial cells (OSE), with OSE from patients at high risk and with ovarian cancer.
RESULTS: Seven surface kinases, ALK, EPHA5, EPHB1, ERBB4, INSRR, PTK, and TGFbetaR1 displayed a distinctive linear trend in expression from normal, highrisk, and malignant epithelium. We confirmed these results using semiquantitative reverse transcription-polymerase chain reaction and tissue array of 202 ovarian cancer samples. A strong correlate was shown between disease-free survival and the expression of ERBB4. DNA sequencing revealed two novel mutations in ERBB4 in two cancer samples.
CONCLUSIONS: A distinct subset of the ovarian surface kinome is altered in the transition from high risk to invasive cancer and genetic mutation is not a dominant mechanism for these modifications. These results have significant implications for early detection and targeted therapeutic approaches for women at high risk of developing ovarian cancer.

Entities:  

Year:  2009        PMID: 19956396      PMCID: PMC2781076          DOI: 10.1593/tlo.09199

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  23 in total

1.  Gene expression profiles in hypoxic preconditioning using cDNA microarray analysis: altered expression of an angiogenic factor, carcinoembryonic antigen-related cell adhesion molecule 1.

Authors:  Wen-Jone Chen; Huei-Wen Chen; Sung-Liang Yu; Chien-Hua Huang; Tzung-Dau Wang; Jeremy J W Chen; Chiang-Ting Chien; Hsuan-Yu Chen; Pan-Chyr Yang; Yuan-Teh Lee
Journal:  Shock       Date:  2005-08       Impact factor: 3.454

2.  Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells.

Authors:  C I Sartor; H Zhou; E Kozlowska; K Guttridge; E Kawata; L Caskey; J Harrelson; N Hynes; S Ethier; B Calvo; H S Earp
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

Review 3.  Targeting HER2 in other tumor types.

Authors:  S Scholl; P Beuzeboc; P Pouillart
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

4.  Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas.

Authors:  Neali D Hendrix; Rong Wu; Rork Kuick; Donald R Schwartz; Eric R Fearon; Kathleen R Cho
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

5.  Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer.

Authors:  L M Gilmour; K G Macleod; A McCaig; W J Gullick; J F Smyth; S P Langdon
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

6.  Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival.

Authors:  Peter Vajkoczy; Pjotr Knyazev; Andrea Kunkel; Hans-Holger Capelle; Sandra Behrndt; Hendrik von Tengg-Kobligk; Fabian Kiessling; Uta Eichelsbacher; Marco Essig; Tracy-Ann Read; Ralf Erber; Axel Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

7.  Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities.

Authors:  Gregory A Vidal; Anjali Naresh; Luis Marrero; Frank E Jones
Journal:  J Biol Chem       Date:  2005-03-03       Impact factor: 5.157

8.  Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.

Authors:  Caroline J Witton; Jonathan R Reeves; James J Going; Timothy G Cooke; John M S Bartlett
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

9.  EphA2 overexpression promotes ovarian cancer growth.

Authors:  Chunhua Lu; Mian M K Shahzad; Hua Wang; Charles N Landen; Seung W Kim; Julie Allen; Alpa M Nick; Nicholas Jennings; Michael S Kinch; Menashe Bar-Eli; Anil K Sood
Journal:  Cancer Biol Ther       Date:  2008-04-19       Impact factor: 4.742

10.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas.

Authors:  Donald R Schwartz; Sharon L R Kardia; Kerby A Shedden; Rork Kuick; George Michailidis; Jeremy M G Taylor; David E Misek; Rong Wu; Yali Zhai; Danielle M Darrah; Heather Reed; Lora H Ellenson; Thomas J Giordano; Eric R Fearon; Samir M Hanash; Kathleen R Cho
Journal:  Cancer Res       Date:  2002-08-15       Impact factor: 12.701

View more
  14 in total

1.  Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence.

Authors:  Christine Gruessner; Angelika Gruessner; Katherine Glaser; Nisreen AbuShahin; Yi Zhou; Cynthia Laughren; Heather Wright; Samantha Pinkerton; Xiaofang Yi; Jha'nae Stoffer; Masoud Azodi; Wenxin Zheng; Setsuko K Chambers
Journal:  Cancer Prev Res (Phila)       Date:  2014-06-20

2.  High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.

Authors:  Suzy Davies; Anna Holmes; Lesley Lomo; Mara P Steinkamp; Huining Kang; Carolyn Y Muller; Bridget S Wilson
Journal:  Int J Gynecol Pathol       Date:  2014-07       Impact factor: 2.762

3.  Biomarkers and endosalpingiosis in the ovarian and tubal microenvironment of women at high-risk for pelvic serous carcinoma.

Authors:  Christine Gruessner; Angelika Gruessner; Katherine Glaser; Nisreen Abushahin; Cynthia Laughren; Wenxin Zheng; Setsuko K Chambers
Journal:  Am J Cancer Res       Date:  2014-01-15       Impact factor: 6.166

4.  PTK7 protein is decreased in epithelial ovarian carcinomas with poor prognosis.

Authors:  Haiyan Wang; Guimei Li; Yongxiang Yin; Jianjun Wang; Hai Wang; Wei Wei; Qing Guo; Henghui Ma; Qunli Shi; Xiaojun Zhou; Jiandong Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

5.  Frequent MAGE mutations in human melanoma.

Authors:  Otavia L Caballero; Qi Zhao; Donata Rimoldi; Brian J Stevenson; Suzanne Svobodová; Sylvie Devalle; Ute F Röhrig; Anna Pagotto; Olivier Michielin; Daniel Speiser; Jedd D Wolchok; Cailian Liu; Tanja Pejovic; Kunle Odunsi; Francis Brasseur; Benoit J Van den Eynde; Lloyd J Old; Xin Lu; Jonathan Cebon; Robert L Strausberg; Andrew J Simpson
Journal:  PLoS One       Date:  2010-09-16       Impact factor: 3.240

6.  Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium.

Authors:  Ana Babic; Daniel W Cramer; Linda E Kelemen; Martin Köbel; Helen Steed; Penelope M Webb; Sharon E Johnatty; Anna deFazio; Diether Lambrechts; Marc T Goodman; Florian Heitz; Keitaro Matsuo; Satoyo Hosono; Beth Y Karlan; Allan Jensen; Susanne K Kjær; Ellen L Goode; Tanja Pejovic; Melissa Moffitt; Estrid Høgdall; Claus Høgdall; Iain McNeish; Kathryn L Terry
Journal:  Cancer Causes Control       Date:  2017-01-03       Impact factor: 2.506

7.  Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data.

Authors:  Runjun D Kumar; Li-Wei Chang; Matthew J Ellis; Ron Bose
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

Review 8.  The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer.

Authors:  Q Sheng; J Liu
Journal:  Br J Cancer       Date:  2011-03-01       Impact factor: 7.640

9.  Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer.

Authors:  Tuan Zea Tan; Qing Hao Miow; Ruby Yun-Ju Huang; Meng Kang Wong; Jieru Ye; Jieying Amelia Lau; Meng Chu Wu; Luqman Hakim Bin Abdul Hadi; Richie Soong; Mahesh Choolani; Ben Davidson; Jahn M Nesland; Ling-Zhi Wang; Noriomi Matsumura; Masaki Mandai; Ikuo Konishi; Boon-Cher Goh; Jeffrey T Chang; Jean Paul Thiery; Seiichi Mori
Journal:  EMBO Mol Med       Date:  2013-05-13       Impact factor: 12.137

10.  NotI microarrays: novel epigenetic markers for early detection and prognosis of high grade serous ovarian cancer.

Authors:  Vladimir Kashuba; Alexey A Dmitriev; George S Krasnov; Tatiana Pavlova; Ilya Ignatjev; Vasily V Gordiyuk; Anna V Gerashchenko; Eleonora A Braga; Surya P Yenamandra; Michael Lerman; Vera N Senchenko; Eugene Zabarovsky
Journal:  Int J Mol Sci       Date:  2012-10-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.